Adds depth and durability to Mallinckrodt's Specialty Brands segment; further diversifies its portfolio with an innovative high-value, high-margin drug-device system used in hospitals and major medical centers in more than...
-- Enters into definitive agreement to acquire Therakos, Inc. for $1.325 billion from The Gores Group, LLC ---Transaction expected to be accretive by no less than $0.10 per share to...
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
The Therakos company does not review or control the content of non-Therakos company websites. Therakos privacy procedures do not apply to the owners of a non-Therakos Group websites.